ADVM Quote, Financials, Valuation and Earnings

Pfizer Inc. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of 21.32%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat Pfizer Inc.'s return on equity of 10.84%.

Adverum Biotechnologies, Inc. has a consensus price target of $5.00, signalling upside risk potential of 14.68%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Adverum Biotechnologies, Inc. has higher upside potential than Pfizer Inc., analysts believe Adverum Biotechnologies, Inc. is more attractive than Pfizer Inc..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Adverum Biotechnologies, Inc.'s net income of -$47.7M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Quantum-Si, Inc. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of -6467.94%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat Quantum-Si, Inc.'s return on equity of -51.75%.

Adverum Biotechnologies, Inc. has a consensus price target of $5.00, signalling upside risk potential of 14.68%. On the other hand Quantum-Si, Inc. has an analysts' consensus of $2.68 which suggests that it could grow by 104.83%. Given that Quantum-Si, Inc. has higher upside potential than Adverum Biotechnologies, Inc., analysts believe Quantum-Si, Inc. is more attractive than Adverum Biotechnologies, Inc..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison Quantum-Si, Inc. has a beta of 2.983, suggesting its more volatile than the S&P 500 by 198.267%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. Quantum-Si, Inc. pays out -- of its earnings as a dividend.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than Quantum-Si, Inc. quarterly revenues of $552K. Adverum Biotechnologies, Inc.'s net income of -$47.7M is lower than Quantum-Si, Inc.'s net income of -$35.7M. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while Quantum-Si, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 74.35x for Quantum-Si, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of -3135.32%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Adverum Biotechnologies, Inc. has a consensus price target of $5.00, signalling upside risk potential of 14.68%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 59.09%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Adverum Biotechnologies, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Adverum Biotechnologies, Inc..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Adverum Biotechnologies, Inc.'s net income of -$47.7M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 40.36x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

X4 Pharmaceuticals, Inc. has a net margin of -2713.4% compared to Adverum Biotechnologies, Inc.'s net margin of -1689.24%. Adverum Biotechnologies, Inc.'s return on equity of -558.69% beat X4 Pharmaceuticals, Inc.'s return on equity of -279.19%.

Adverum Biotechnologies, Inc. has a consensus price target of $5.00, signalling upside risk potential of 14.68%. On the other hand X4 Pharmaceuticals, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 81%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Adverum Biotechnologies, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Adverum Biotechnologies, Inc..

Adverum Biotechnologies, Inc. has a beta of 0.869, which suggesting that the stock is 13.055% less volatile than S&P 500. In comparison X4 Pharmaceuticals, Inc. has a beta of 0.421, suggesting its less volatile than the S&P 500 by 57.861%.

Adverum Biotechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. X4 Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies, Inc. pays -- of its earnings as a dividend. X4 Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adverum Biotechnologies, Inc. quarterly revenues are --, which are smaller than X4 Pharmaceuticals, Inc. quarterly revenues of $1.8M. Adverum Biotechnologies, Inc.'s net income of -$47.7M is lower than X4 Pharmaceuticals, Inc.'s net income of -$29.8M. Notably, Adverum Biotechnologies, Inc.'s price-to-earnings ratio is -- while X4 Pharmaceuticals, Inc.'s PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies, Inc. is 89.16x versus 2.09x for X4 Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.